LSV Asset Management Boosts Stake in Halozyme Therapeutics, Inc. $HALO

LSV Asset Management grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.9% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,266,027 shares of the biopharmaceutical company’s stock after buying an additional 10,787 shares during the period. LSV Asset Management’s holdings in Halozyme Therapeutics were worth $92,850,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. CWM LLC boosted its position in shares of Halozyme Therapeutics by 2,136.0% in the third quarter. CWM LLC now owns 23,881 shares of the biopharmaceutical company’s stock worth $1,751,000 after purchasing an additional 22,813 shares during the period. Arbor Investment Advisors LLC purchased a new stake in shares of Halozyme Therapeutics during the third quarter worth about $1,316,000. Monument Capital Management bought a new stake in Halozyme Therapeutics during the 3rd quarter valued at approximately $2,015,000. Pacer Advisors Inc. raised its stake in Halozyme Therapeutics by 2,054.7% during the 3rd quarter. Pacer Advisors Inc. now owns 478,874 shares of the biopharmaceutical company’s stock valued at $35,121,000 after purchasing an additional 456,649 shares during the period. Finally, Cardinal Capital Management purchased a new position in Halozyme Therapeutics in the 3rd quarter worth approximately $1,303,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Down 3.3%

Shares of NASDAQ HALO opened at $76.92 on Friday. The firm’s 50-day moving average price is $70.53 and its 200-day moving average price is $69.67. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59. The stock has a market capitalization of $9.05 billion, a price-to-earnings ratio of 16.19, a P/E/G ratio of 0.33 and a beta of 0.97. Halozyme Therapeutics, Inc. has a 12-month low of $47.50 and a 12-month high of $82.22.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $78.64, for a total value of $786,400.00. Following the completion of the transaction, the chief executive officer owned 708,719 shares in the company, valued at approximately $55,733,662.16. The trade was a 1.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the transaction, the director directly owned 40,123 shares in the company, valued at approximately $2,818,640.75. This represents a 4.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 49,398 shares of company stock worth $3,650,592 over the last three months. 2.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on HALO shares. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, January 29th. JPMorgan Chase & Co. lifted their price target on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a report on Monday, October 27th. The Goldman Sachs Group reiterated a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Morgan Stanley dropped their price objective on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a report on Monday, October 20th. Finally, TD Cowen lifted their target price on Halozyme Therapeutics from $79.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $78.80.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.